re: STML If you listen to today's presentation at Oppenheimer, the CEO Bergstein addresses some of the toxicity concerns. https://www.veracast.com/webcasts/opco/healthcare2015/25211513107.cfm?0.143472521889 Overall, I agree with "Oldberkeley's" assessment. Hard to believe that this stock is selling at virtually cash vale. The resignation of CMO, Dr. Eric Rowinsky, is a bit of a red flag to me, but he is staying on as a "consultant" for two years, whatever that means. Hammer seems on the fence about STML. Bladerunner